2022
DOI: 10.1124/molpharm.121.000480
|View full text |Cite
|
Sign up to set email alerts
|

Mechanisms Underlying the Inhibition of KV1.3 Channel by Scorpion Toxin ImKTX58

Abstract: α-KTX, alpha-potassium channel toxin peptides; ADWX-1, autoimmune drug from Wenxin group; APC, anterior piriform cortex; BK channel, large conductance voltage and Ca 2+ -activated potassium channel; CS, cysteine-stabilized; ChTX, Charybdotoxin; DMEM, Dulbecco's modified Eagle's medium; DRG, dorsal root ganglion; E. coli, Escherichia coli; GPCR, G protein-coupled receptor; HPLC, High Performance Liquid Chromatography; IC 50 , concentration of half-maximal inhibition; IL-2, interleukin-2; ImKTX58, number 58 pota… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 45 publications
0
2
0
Order By: Relevance
“…Crystal Data for Euphofischeroid B (2). C 29 H 38 O 7 , M = 498.59 g/ mol, orthorhombic, space group P2 1 2 1 2 1 (no.…”
Section: ■ Experimental Sectionmentioning
confidence: 99%
See 1 more Smart Citation
“…Crystal Data for Euphofischeroid B (2). C 29 H 38 O 7 , M = 498.59 g/ mol, orthorhombic, space group P2 1 2 1 2 1 (no.…”
Section: ■ Experimental Sectionmentioning
confidence: 99%
“…Autoimmune diseases are stimulated by excessive immune responses originating from an immune malfunction. Such health conditions affect physiological and psychological human health all around the world. , Although commonly used autoimmune drugs, such as steroids and cyclophosphamide, can alleviate symptoms promoted by autoimmune responses, the lack of selectivity makes these drugs of limited clinical effectiveness to treat conditions resulting from immune responses and increases the chances of occurring secondary infections and serious side effects . Therefore, it is urgent to develop therapeutic targets to treat effectively autoimmune diseases without affecting the normal protective immune system.…”
mentioning
confidence: 99%